glp 1 agonist tirzepatide Understand GLP-1/GIP Dual and Its Effect on Current Weight Loss Therapy Shifting the Scales: Tirzepatide's Breakthrough
Description
This allows patients to stay engaged with their plan while receiving continued guidance throughout their weight loss program
Retatrutide's triple-agonist profile targets weight, type 2 diabetes control and obesity-related conditions such as sleep apnea and knee osteoarthritis in one therapy, which could appeal to payers and health systems looking at total disease burden across specialties
doi: 10.1515/jpem-2022-0074 65 ButlerMGGargU
Hale, Thomas Wright
doi: 10.1016/j.jdiacomp.2020.107723
